The result of the U.S. election has reduced some of the uncertainty around the outlook for the biotech sector. Leading up to the election, investors felt jittery about the potential impact of the Democrats making a clean sweep – i.e. winning the Presidency, the House and the Senate. However, the odds are currently in favour of the Senate remaining Republican, reducing the likelihood of major healthcare reform.
Published on 21st December 2020